Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Start-Up News September 2007

Executive Summary

TheraCardia has a portfolio of natural biopolymers that it will develop for stents; initially, for stent coatings, and soon, a bioabsorbable stent that avoids inflammation and contributes to endothelization, without the need for a drug. Surgeon-founded Aragon Surgical will develop a platform of products to make surgeries faster and safer. Intelect Medical is developing new neurostimulation devices that, it believes, offer advances over the devices of predecessors. It's initial target application is traumatic brain injury.

You may also be interested in...



Arterial Remodeling Technologies

Paris-based Arterial Remodeling Technologies is developing a bioabsorbable stent that may not require the use of anti-inflammatories.

Neurostimulation Market Expanding

According to Medtech Insight’s recently published report, US Markets for Neurostimulation Products, the frontier for neural stimulation is expanding rapidly, representing a $628 million market in 2006 that is forecast to grow by over 20% each year to produce sales approaching $2 billion in 2012. Topics discussed include implantable pulse generators, device reimbursement, and current and emerging applications for neurostimulation.

Neurostimulation's Billion-Dollar Markets

Beyond the functional stimulation of muscles to get them moving, electrical stimulation can also operate on blood vessels, membranes, and receptors-targets in the body once regarded as the domain of pharmaceuticals. Indeed, driving sales of $2 billion in the neurostimulation industry in 2005 and growth rates of almost 20% going forward, are large-market clinical indications that haven't been well-served by drugs: pain, epilepsy, depression, stroke, urinary incontinence, Parkinson's disease, and obsessive-compulsive disorder. For some of these disorders, chronic neurostimulation-of the deep brain, the spinal cord, the vagus and other nerves-promises site-specific, side-effect free and reversible therapies that have the potential to be efficacious where drugs can't.

Related Content

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

MT035109

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel